GlassScriptPhysician profile
Michelle Asseo
NPI 1841077500
$4,071.58
in general payments reported to CMS, 2019-2025
25 companies · $2,113 in 2025
The $2,113 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $117 · 2024: $1,841 · 2025: $2,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,021 · Education: $50.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,020.59 |
| Education | $50.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,206.94 | 2023-2025 | |
| Janssen Biotech, INC. | $835.58 | 2024-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $326.05 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $313.18 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Lilly USA, LLC | $212.49 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $170.93 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $157.89 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $108.74 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $101.90 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.08 | 2024-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $96.02 | 2024-2025 | Zenpep |
| Madrigal Pharmaceuticals | $82.26 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $50.46 | 2024-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $39.31 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $37.79 | 2024 | Sucraid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $33.47 | 2024-2025 | Pancreaze |
| Braintree Laboratories, INC. | $28.17 | 2023-2024 | Suflave, Sutab |
| Genzyme Corporation | $27.11 | 2025 | |
| Celltrion USA INC. | $26.18 | 2025 | Vegzelma |
| Janssen Scientific Affairs, LLC | $21.42 | 2024 | |
| Pfizer INC. | $20.73 | 2024 | |
| Evoke Pharma, INC. | $20.43 | 2024 | |
| Merck Sharp & Dohme LLC | $19.98 | 2024 | Dificid |
| Novo Nordisk INC | $19.31 | 2025 | Wegovy |
| Redhill Biopharma INC. | $18.16 | 2024 | Talicia, Aemcolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Asseo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.